BioCentury
ARTICLE | Clinical News

New data show survival benefit of Biogen's Spinraza

January 14, 2017 1:21 AM UTC

Newly released data showed that Spinraza nusinersen from Biogen Inc. (NASDAQ:BIIB) met a second primary endpoint of the Phase III ENDEAR study to treat spinal muscular atrophy. The therapy significantly reduced risk of death or permanent ventilation at an end of study analysis.

FDA approved Spinraza last month to treat SMA. It is the first drug approved in the indication (see BioCentury Extra, Dec. 23, 2016)...

BCIQ Company Profiles

AveXis Inc.

Biogen Inc.

BCIQ Target Profiles

SMN2